Reviewing VYNE Therapeutics (NASDAQ:VYNE) and Corbus Pharmaceuticals (NASDAQ:CRBP)

VYNE Therapeutics (NASDAQ:VYNE) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares VYNE Therapeutics and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Institutional and Insider Ownership

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares VYNE Therapeutics and Corbus Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570,000.00	37.80	-$26.48 million	($0.38)	-1.70
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.51

VYNE Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for VYNE Therapeutics and Corbus Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1	3	0	0	1.75
Corbus Pharmaceuticals	2	0	9	1	2.75

Corbus Pharmaceuticals has a consensus target price of $40.67, suggesting a potential upside of 363.17%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than VYNE Therapeutics.

Summary

Corbus Pharmaceuticals beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.